1274P - ALK and EGFR mutation analysis in a phase II trial of cisplatin/pemetrexed in Japanese patients with advanced non-squamous non-small cell lung cancer

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Translational Research
Non-Small Cell Lung Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter Noriko Yanagitani
Authors N. Yanagitani1, K. Kaburaki1, F. Ohyanagi1, K. Kudo1, A. Horiike1, N. Motoi2, K. Takeuchi2, Y. Ishikawa2, T. Horai1, M. Nishio1
  • 1Thoracic Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 1358550 - Tokyo/JP
  • 2Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 1358550 - Tokyo/JP



Recently, ethnic differences and genotypes such as EGFR mutation or fusion gene (ALK translocation) are important factors in non-small cell lung cancer (NSCLC) treatment. Pemetrexed (P)/cisplatin (C) is one of the standard treatments for advanced non-squamous (Nsq) NSCLC. However, the efficacy of the CP regimen has not been well examined in Japanese Nsq NSCLC patients; furthermore, the difference in efficacy between genotypes was not thoroughly examined. Therefore, the present study was conducted to evaluate the efficacy of the CP regimen in Japanese Nsq NSCLC patients, and to determine whether EGFR mutation and ALK translocation impacted the treatment.


This study was conducted from May 2009 to December 2010. Patients were eligible for this study if they had histologically or cytologically confirmed recurrent or metastatic Nsq NSCLC previously untreated with chemotherapy, an ECOG performance status of 0 or 1, life expectancy of more than 12 weeks, and adequate organ function. Patients received C (75 mg/m2) plus P (500 mg/m2) on day 1 every 3 weeks. Of the 50 patients initially enrolled, 49 were evaluated, and 43 tumor samples were available for analysis. Most patients were male (80%), and 80% of the patients had adenocarcinoma. The primary endpoint was the response rate that was evaluated.

according to RECIST.

EGFR mutation was examined using PCR-based methods, and the ALK fusion protein was examined using a highly sensitive IHC method in the available tumor specimens.


The objective response rate and disease control rate in all patients were 44.9% and 79.6%, respectively. The median progression-free survival was 4.4 months, and the 1-year survival was 73.5%. Toxicities were mild; no new toxicity profile was identified. Among the 43 samples, the following mutations were identified: 9 EGFRm (21%), 5 ALK (12%), and 29 wild-type (67%). Objective response was observed in 6 (66.7%) EGFRm, 2 (40%) ALK (+), and 13 (44.8%) wild-type mutations.


Although the CP regimen demonstrates consistent efficacy in Japanese Nsq NSCLC patients, EGFR mutation and ALK translocation may have impacted this treatment.


All authors have declared no conflicts of interest.